Peterson Jeffrey R, Bickford Lincoln C, Morgan David, Kim Annette S, Ouerfelli Ouathek, Kirschner Marc W, Rosen Michael K
Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.
Nat Struct Mol Biol. 2004 Aug;11(8):747-55. doi: 10.1038/nsmb796. Epub 2004 Jul 4.
Current drug discovery efforts focus primarily on proteins with defined enzymatic or small molecule binding sites. Autoregulatory domains represent attractive alternative targets for small molecule inhibitors because they also occur in noncatalytic proteins and because allosteric inhibitors may avoid specificity problems inherent in active site-directed inhibitors. We report here the identification of wiskostatin, a chemical inhibitor of the neural Wiskott-Aldrich syndrome protein (N-WASP). Wiskostatin interacts with a cleft in the regulatory GTPase-binding domain (GBD) of WASP in the solution structure of the complex. Wiskostatin induces folding of the isolated, unstructured GBD into its autoinhibited conformation, suggesting that wiskostatin functions by stabilizing N-WASP in its autoinhibited state. The use of small molecules to bias conformational equilibria represents a potentially general strategy for chemical inhibition of autoinhibited proteins, even in cases where such sites have not been naturally evolved in a target.
当前的药物研发工作主要集中在具有明确酶活性或小分子结合位点的蛋白质上。自调节结构域是小分子抑制剂有吸引力的替代靶点,因为它们也存在于非催化蛋白中,并且变构抑制剂可能避免活性位点导向抑制剂固有的特异性问题。我们在此报告了威斯科他汀的鉴定,它是神经威斯科特-奥尔德里奇综合征蛋白(N-WASP)的一种化学抑制剂。在复合物的溶液结构中,威斯科他汀与WASP调节性GTP酶结合结构域(GBD)中的一个裂隙相互作用。威斯科他汀诱导分离的无结构GBD折叠成其自身抑制构象,这表明威斯科他汀通过将N-WASP稳定在其自身抑制状态发挥作用。使用小分子来偏向构象平衡代表了一种潜在的通用策略,用于化学抑制自身抑制的蛋白质,即使在靶点中此类位点并非自然进化产生的情况下也是如此。